Clinical Activity of Elraglusib with Gemcitabine Plus Nab-paclitaxel in First-Line Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma By Ogkologos - April 27, 2026 159 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the phase II study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR EMA Recommends Granting a Marketing Authorisation for the Medicinal Product Nyvepria October 2, 2020 A urine test for bladder cancer: What’s the latest? April 16, 2022 FDA Approves Durvalumab for Muscle Invasive Bladder Cancer May 2, 2025 HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours July 30, 2025 Load more HOT NEWS Foodie Friday: What to do with all these zucchini? Outcome of EMA Assessment on Use of Lutetium (177Lu) in Treatment... The most important cancer research stories of 2022 EMA Recommends Extension of Therapeutic Indications for Durvalumab and Adopts a...
